APL-103 / Zhejiang Bossan Pharma, Apollomics - LARVOL DELTA

ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. (PubMed, Nat Commun) - "Moreover, combining EGFR inhibitor ES-072 with anti-CTLA4 immunotherapy results in an additive effect on both tumor growth and cytotoxic T cell activation. Our results delineate a mechanism of PD-L1 degradation and cancer escape from immunity via EGFR-GSK3α-ARIH1 signaling and suggest GSK3α and ARIH1 might be potential drug targets to boost anti-tumor immunity and enhance immunotherapies."

IO biomarker • Journal • Oncology • Targeted Protein Degradation

[VIRTUAL] First-in-Human Phase I Study of ES-072, an oral mutant-selective EGFR T790M inhibitor, in Non-Small Cell Lung Cancer (CTS-China 2020) - No abstract available

P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer. (PubMed, Clin Lung Cancer) - "ES-072 was safe and well tolerated in NSCLC patients harboring EGFR T790M mutations, and adverse events were controllable and reversible. A RP2D of 300 mg once daily was determined, and preliminary investigations showed promising antitumor activity."

Journal • P1 data • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR